Patent intelligence · US
US 12162855
Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
Patent details — US 12162855
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 10, 2024
- Expiration
- Dec 5, 2044
- Applicant
- THE TRUSTEES OF PRINCETON UNIVERSITY
- Claims
- 2
- CPC classes
- A61P, A61P35/00
Quick answer
US 12162855 (Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers) is held by THE TRUSTEES OF PRINCETON UNIVERSITY. Status: granted. Granted Dec 10, 2024. Expires Dec 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- THE TRUSTEES OF PRINCETON UNIVERSITY
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61P, A61P35/00
More from THE TRUSTEES OF PRINCETON UNIVERSITY
Related pharmaceutical patents in our USPTO index.
-
US 12419831
Hydrocortisone oral liquid formulations
granted -
US 12396974
Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
granted -
US 12357582
Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
granted -
US 12343324
Dihydromyricetin hot melt extrusion formulations and methods for forming them
granted -
US 12329816
Immunotherapy with metabolic enzyme expression
granted -
US 12209256
System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction
granted -
US 12195768
System and method for modulating stress granule assembly
granted -
US 12186436
Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
granted
Frequently asked questions
What is US patent 12162855?
US 12162855 (Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers) is held by THE TRUSTEES OF PRINCETON UNIVERSITY. Status: granted. Granted Dec 10, 2024. Expires Dec 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12162855?
THE TRUSTEES OF PRINCETON UNIVERSITY is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 163 pharmaceutical patents for this assignee.
When does US 12162855 expire?
Our index shows an expiration date of Dec 5, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.